Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy. It is characterized by progressive weakness and myotonia, which preferentially affects the craniofacial, hand, and distal leg muscles. Many patients also experience difficulties with cognition, cardiac arrhythmias, respiratory failure, or cataracts. Currently there is no treatment to slow progression or reverse the symptoms.

Am I eligible? Learn More

Detailed Description

The goal of this observational study is to characterize long-term disease progression over at least 4 years in at least 1,000 adults with myotonic dystrophy type 1 (DM1).

The main questions this study aims to answer are:

  1. How do clinical measures, such as walking speed, hand function, and muscle strength, change over a multi-year period in people with DM1?
  2. Can long-term changes in slowly progressive measures, like heart rhythms (ECG) and lung function (FVC), be accurately captured and used as biomarkers for the disease over time?

Simple Text Block

You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.

Call 1800-9860-568 now to find out if you are eligible.

Find a site near you

Age icon
Age
18 - 70
Gender icon
Gender
All
NCT ID icon
NCT ID
NCT07700225
Phase icon
Phase
-1
Status icon
Status
Recruiting Now
Medical Condition icon
Medical Condition
Muscular Dystrophy

How is Plaque Psoriasis treated?

Medical Condition icon
Medical Condition
A short sentence to introduce what to expect in the about condition section
Learn more
Study icon
The Study
A short sentence to introduce what to expect in the about condition section
Learn more
Clinical Trials icon
About Clinical Trials
A short sentence to introduce what to expect in the about condition section
Learn more

Your Journey

01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.

Call 1800-9860-568 now to find out if you are eligible.